close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

24.46 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
US-India Trade War Escalates: New Tariffs Spark Inflation Fears and Corporate Profit Warnings
The global trade landscape has once again been rattled as the United States officially implemented sweeping new tariffs on a significant portion of imports from India. Effective August 27, 2025, these... 
Via MarketMinute
Topics Economy Government Supply Chain
Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda
Teva launches the first U.S. generic version of Saxenda for weight loss after FDA approval, expanding its portfolio with a key GLP-1 therapy. 
Via Benzinga
FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk
Teva Pharmaceutical is joining compounders, knocking off one of Novo Nordisk's weight-loss drugs. 
Via Investor's Business Daily
This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More
Via Stocktwits
Earnings Scheduled For July 30, 2025
 
Via Benzinga
How Do Investors Really Feel About Teva Pharmaceutical Indus?
 
Via Benzinga
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive Quarters
Duquesne's billionaire boss bid adieu to Wall Street's hottest artificial intelligence (AI) stock in favor of one of the cheapest pharmaceutical stocks on the planet. 
Via The Motley Fool
Topics Artificial Intelligence
How Is The Market Feeling About Teva Pharmaceutical Indus?
 
Via Benzinga
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy
Teva raised 2025 guidance for Austedo, Ajovy, and Uzedy after Q2 earnings beat estimates, despite missing revenue expectations. 
Via Benzinga
Topics Earnings
Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings
Teva stock is trading below key levels. 
Via Investor's Business Daily
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong
Teva anticipates EBITDA recovery post-2025 as Austedo and Uzedy grow and generic Revlimid faces rising competition. 
Via Benzinga
A Glimpse of Teva Pharmaceutical Indus's Earnings Potential
 
Via Benzinga
Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive Quarters
Duquesne Family Office's billionaire chief dumped his fund's stake in Wall Street's artificial intelligence (AI) darling in favor of two reasonably cheap stocks that have taken off in recent years. 
Via The Motley Fool
Topics Artificial Intelligence
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Looking Into Teva Pharmaceutical Indus's Recent Short Interest
 
Via Benzinga
Teva Releases Q2 2025 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
What Analysts Are Saying About Teva Pharmaceutical Indus Stock
 
Via Benzinga
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:TEVA),(NASDAQ:CTOR),(NYSE:ADCT),(NYSE:OSTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?
Via The Motley Fool
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters
Duquesne Family Office's billionaire chief sold every share of Wall Street's hottest artificial intelligence (AI) stock in favor of a drugmaker whose shares have surged 142% in two years. 
Via The Motley Fool
Topics Artificial Intelligence Economy
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook. 
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today